MISSION COVID SURAKSHA
The Central Government has launched ‘Mission COVID Suraksha’ in order to facilitate the development of approximately 5-6 COVID-19 vaccine candidates. According to the Department of Biotechnology, it will also ensure that the vaccine candidates are brought closure to introduction and licensure in the market. The Government of India has announced the stimulus package of Rs. 900 crore for the Mission COVID Suraksha, the Indian Covid-19 Vaccine Development Mission, which will help the development process of the vaccine candidates.
The DBT further informed that the mission focuses on the COVID-19 vaccine development with end-to-end focus from the preclinical stage through clinical development as well as manufacturing and regulatory facilitation.
AIMS AND OBJECTIVE OF THE MISSION
Mission COVID Suraksha is India’s targeted effort to enable the development of indigenous, affordable and accessible vaccines for the country and will complement the ongoing mission of Atmanirbhar Bharat. The Centre had announced this package during the third economic stimulus. The Mission with its end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment, would consolidate all available and funded resources towards accelerated product development.
Phase-I of the Mission has been allotted Rs. 900 Crore for a period of 12 months. The grant will be provided to the Department of Biotechnology (DBT) for Research and Development (R&D) of Indian Covid-19 vaccines. To facilitate the pre-clinical and clinical development as well as licensure of vaccine candidates that are in the clinical stages or are ready to enter the clinical stages of development.
The mission’s aim will also be to establish clinical trial sites. It will also strengthen the central laboratories, existing immunoassay laboratories, and suitable facilities for production studies, animal studies, and other test facilities for supporting vaccine development.
Supporting the development of common harmonized protocols, data management systems, training, regulatory submissions, accreditations, internal and external quality management systems. Under the mission, cell line development, capabilities for process development, manufacturing of Good Manufacturing Practices, clinical trials, and batches for animal toxicology will also be supported. The key portion will be the development of a suitable target product profile so that the vaccines that are being introduced through mission have characteristics that are applicable to India.
OTHER KEY POINTS OF THE MISSION
It will be led by DBT and implemented by a dedicated Mission Implementation Unit at the Biotechnology Industry Research Assistance Council (BIRAC). The existing activities under National Bio Pharma Mission (NBM) and Ind-CEPI Mission will provide complementary strengths to this Mission. The DBT is supporting the implementation of the Ind-CEPI Mission, “Epidemic preparedness through rapid vaccine development: Support of Indian vaccine development aligned with the global initiative of the Coalition for Epidemic Preparedness Innovations (CEPI)”. The Ind-CEPI Mission was approved in March 2019.
Accelerating pre-clinical and clinical development. Licensure of Covid-19 vaccine candidates that are currently in clinical stages or ready to enter the clinical stage of development. Strengthening the existing central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support the vaccine development. Supporting the development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations. Supporting capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials. Developing suitable Target Product Profile so that vaccines being introduced through the mission have preferred characteristics applicable to India.
OTHER COVID-19 VACCINE CANDIDATES
A total of 10 vaccine candidates have been supported by DBT so far at both academia and industry and as on date and 5 vaccine candidates are in human trials.
• Covishield: The Serum Institute of India (SII) is conducting the phase-3 trial of the Oxford-Astrazeneca Covid-19 vaccine.
• Covaxin: The indigenously developed Bharat Biotech and the Indian Council of Medical Research (ICMR) vaccine has already started the phase III clinical trial.
• ZyCoV-D: Indigenously developed vaccine by Zydus Cadila has completed the phase-2 clinical trial in the country.
• Sputnik V: The combined phase 2 and 3 clinical trials of the Russian Covid-19 vaccine Sputnik V in India are about to get started.
• BNT162b2: India is focusing on training for conducting phase II and III human clinical trials of the Pfizer's Covid-19 vaccine candidate along lines of India’s regulatory mechanism.
WHAT IS CLINICAL TRIAL?
It is a systematic study to generate data for discovering or verifying the clinical and pharmacological profile (including pharmacodynamic and pharmacokinetic) or adverse effects of a new drug on humans. It is the only way of establishing the safety and efficacy of any drug before its introduction in the market for human use and is preceded by animal trials where the efficacy and side effects are observed in animals and an estimated drug dose is established. Clinical trials of drugs developed in India have to undergo all four phases of trials in India.
Phase I or clinical pharmacology trials or “first in man” study.
Phase II or exploratory trials.
Phase III or confirmatory trials.
Phase IV trials or post-marketing phase.
QUESTIONS (1-5)
Q.1 Which of the following Mission was launched in order to facilitate the development of approximately 5-6 COVID-19 vaccine candidates?
A. Mission Covid Security
B. Mission Covid Suraksha: ANSWER
C. Mission CoviDefeat
D. None of the above
Q.2 The Government of India has announced the stimulus package of how much Rs. for the Indian Covid-19 Vaccine Development Mission?
A. Rs. 800 crore
B. Rs. 900 crore: ANSWER
C. Rs. 1000 crore
D. Rs. 1200 crore
Q.3 Which of the following statements is/are Correct regarding the Mission initiated by the government?
A. Enable the development of indigenous vaccines for the country.
B. Phase-I of the Mission has been allotted Rs. 900 Crore.
C. The grant will be provided to the CSIR for Research and Development (R&D) of Indian Covid-19 vaccines: ANSWER
D. None of the above
Q.4 Serum Institute of India (SII) which is conducting the phase-3 trial of the Oxford-Astrazeneca Covid-19 vaccine is headquartered at which of the following places?
A. Pune: ANSWER
B. New Delhi
C. Mumbai
D. Ahmedabad
Q.5 Sputnik V which is Covid-19 vaccine is a project of which of the following countries?
A. United Kingdom
B. United States of America
C. France
D. Russia: ANSWER
